Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a

Neurology. 2005 Mar 8;64(5):888-90. doi: 10.1212/01.WNL.0000153570.33845.6A.

Abstract

The authors studied the tolerability of subcutaneous interferon beta-1a (IFNbeta-1a) in 51 patients with early-onset multiple sclerosis. The most frequent systemic adverse effects were flu-like symptoms in 65%. Laboratory abnormalities included asymptomatic leukopenia (27%) and elevated hepatic transaminases (35%). Treatment with IFNbeta-1a was safe and well tolerated in the majority of children and adolescents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / adverse effects
  • Adolescent
  • Age of Onset
  • Central Nervous System / drug effects*
  • Central Nervous System / pathology
  • Central Nervous System / physiopathology
  • Child
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Interferon beta-1a
  • Interferon-beta / administration & dosage*
  • Interferon-beta / adverse effects
  • Leukopenia / chemically induced
  • Leukopenia / immunology
  • Liver / drug effects
  • Liver / physiopathology
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / physiopathology
  • Retrospective Studies
  • Secondary Prevention
  • Transaminases / drug effects
  • Transaminases / metabolism
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Interferon-beta
  • Transaminases
  • Interferon beta-1a